AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01338987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults > 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)
Study NCT01338987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults > 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)
Study NCT01338987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
Study NCT02771899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOS
Description: The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
Study NCT01443871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pure water
Description: Subject will assigned inhale Pure water
Study NCT00714441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle and Activities Education Program (LEAP-AHEAD)
Description: Patients in the LEAP-AHEAD Program arm will be shown a 40-minute interactional DVD and given the Healthy Habits Health Risk Appraisal, at baseline and 20 weeks that asks questions about diabetes self care practices and other health behaviors and gives recommendations in those areas. A score sheet based on the participant's responses will be left with the participant. At intervals from 0 to 44 weeks, patients will receive emailed informational pamphlets on diabetes and its complications, along with live telephone calls to answer any questions and check-in.
Study NCT02771899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EOS
Description: The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
Study NCT03522454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-rich oral nutritional supplement
Description: Ready-to-drink beverage containing 20 g protein and 1.5 g hydroxymethylbutyrate (HMB) per serving, consumed twice daily.
Study NCT03522454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based supervised exercise program
Description: WEBB (Weight-bearing Exercise for Better Balance) program combining walking and weight-bearing exercises to build strength and balance, administered by a trained therapist at the participant's home.
Study NCT03908671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized mRNA Tumor Vaccine
Description: subcutaneous injection with personalized mRNA tumor vaccine
Study NCT04477330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: 1 mA tDCS
Study NCT04477330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle motor training
Description: Visuomotor target tracking task
Study NCT04477330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval speed based treadmill training (HIISTT)
Description: Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.
Study NCT01338987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
Study NCT01338987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.
Study NCT01338987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.
Study NCT01338987 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)
Study NCT01338987 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)
Study NCT01338987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Second choice is Busulfan (with goal steady state of 800-1000) with fludarabine or cyclophosphamide at myeloablative dosing or non-myeloablative dosing.
Study NCT01338987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given with Busulfan as alternative to cyclophosphamide in second transplant setting only
Study NCT04477330 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: High intensity interval speed based treadmill training (HIISTT)
Description: Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.
Study NCT02838199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3
Study NCT01338987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second Allogeneic Bone Marrow Transplantation
Description: Second Allogeneic Bone Marrow Transplantation
Study NCT04445779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before surgical procedure.
Study NCT04445779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coenzyme Q10
Description: Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before surgical procedure.
Study NCT00003034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00003034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranpirnase
Description: Given IV
Study NCT02420418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl-cysteine (NAC)
Description: Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in outpatient smokiing cessation. The dosage will be fixed 1800 mg/day of NAC administered in capsules taken 2 before breakfast and 2 before dinner is equal doses.
Study NCT02420418 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in smoking cessation service
Study NCT01144364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [Mabthera/Rituxan]
Description: Intravenous repeating dose
Study NCT02071953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental adhesive w/out phosphoric acid in post. rest.
Description: Experimental adhesive without phosphoric acid in posterior restorations
Study NCT02071953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental adhesive with phosphoric acid in post. rest.
Description: Experimental adhesive with phosphoric acid in posterior restorations
Study NCT02405949 — intervention group
Intervention type: GENETIC
Intervention: Genetic test
Description: Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .
Study NCT00350649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard CBT
Description: Manualized delivery of CBT by trained clinicians
Study NCT00350649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT+CM/adherence
Description: CBT and Clinical Management for attendance and completing homework
Study NCT00350649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM/abstinence
Description: Contingency Management
Study NCT00350649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CM/abstinence+CBT
Description: Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
Study NCT02451098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin10mg, Ezetimibe10mg
Description: Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)
Study NCT02451098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin10mg, Ezetimibe placebo
Description: Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)
Study NCT02451098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin20mg, Ezetimibe10mg
Description: Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)
Study NCT02451098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin20mg, Ezetimibe placebo
Description: Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)
Study NCT02451098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin40mg, Ezetimibe10mg
Description: Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)
Study NCT02451098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin40mg, Ezetimibe placebo
Description: Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)
Study NCT03166553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemene
Study NCT01601366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Description: The study includes 2 treatment groups: Group I the LNG-IUS group where they will have a LNG IUS inserted for them
Study NCT01601366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined oral contraceptives
Description: Group II: will recite combined oral contraceptives for 6 months
Study NCT01970865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
Study NCT01970865 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Crizotinib
Description: Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
Study NCT04111848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will be assigned into 2 groups (each of 45):~Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour.
Study NCT04111848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine and magnesium
Description: Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
Study NCT00231257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
Description: Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
Study NCT00231257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Brachytherapy
Study NCT03263039 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg Q3W
Study NCT03218163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 Maintenance
Description: Cycle 1 - Days 1, 8, 15, and 22: 4mg/kg IV Cycles 2-12 - Day 1: 4mg/kg IV
Study NCT01699386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Study Formula
Description: feed as lib
Study NCT01699386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Study Formula
Description: feed as lib
Study NCT01458106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB031 (rFVIIIFc)
Description: Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
Study NCT01458106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FVIII (PK subgroup only)
Description: Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
Study NCT05541991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: single dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract
Description: coated tablet with a single dose of standardised rhubarb extract
Study NCT05541991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo coated tablet
Description: coated tablet without active principle
Study NCT05541991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: double dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract
Description: coated tablet with a double dose of standardised rhubarb extract
Study NCT03805308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-arterial Therapy
Description: Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.
Study NCT02441244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visbiome
Description: Visbiome probiotic
Study NCT02441244 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03095118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Intravenously (IV) at a dose of 16 mg/kg once weekly for 8 weeks, followed by once every 2 weeks for eight additional doses
Study NCT03023514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Lipoic acid
Description: 300 mg ALA x2 (1pill orally/12h) to the recipient from the day of the donors pick up until 8 week of pregnancy
Study NCT03023514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Progesterone
Description: 200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
Study NCT03023514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Progesterone
Description: 200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
Study NCT01244061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 1mg twice daily
Study NCT01244061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo twice daily
Study NCT02442583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brochure regarding sedentary behavior
Description: This pilot will occur in two phases. Phase 1 will occur in two steps. In Step 1, we will conduct one-on-one telephone interviews with 15 early stage CRC (colorectal cancer) survivors to obtain their knowledge and insights about sedentary behaviors and ways to reduce them. Their input will be used to help create a brochure on sedentary behaviors. In Step 2, we will conduct one-on-one telephone interviews with 5 early stage CRC survivors to provide feedback about the brochure. In Phase 2, we will recruit 15 CRC survivors. After completing a baseline survey, they will be asked to both wear an ActiGraph and self-report their daily sedentary behaviors for one week. They will receive tailored feedback as to their average weakly levels of sedentary behaviors and receive the brochure. One month post-intervention, they will be asked to take part in telephone survey assessing sedentary behaviors, PA (physical activity), and use of brochure.
Study NCT03992417 — intervention group
Intervention type: DRUG
Intervention: Dupilumab SAR231893 (REGN668)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Study NCT03736629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03833622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Aid Assessment
Description: Provide feedback on a shared decision making tool to aid in discussion on goals of care in the emergency department
Study NCT03624764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparostopic promontofixation using surgical glue
Description: The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by the surgical glue (cyanoacrylate biocompatible adhesive)
Study NCT03624764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparostopic promontofixation using threads
Description: The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by sutures with threads
Study NCT02616185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06755992
Description: PF-06755992 will be administered on Day 1 of Cycles 1 and 2.
Study NCT02616185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06755990
Description: PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
Study NCT02616185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDS-IM Electroporation Device
Description: TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
Study NCT02616185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: PF-06753388 will be administered every 28 days.
Study NCT02616185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: PF-06801591 will be administered every 28 days.
Study NCT02616185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06753512
Description: Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab
Study NCT03617029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcoil
Description: Needle localization with microcoil
Study NCT03617029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipiodol
Description: Needle localization with contrast injection
Study NCT02838199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SAVR
Study NCT00089271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvespimycin hydrochloride
Description: Given IV
Study NCT00089271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01541527 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood test
Description: One blood test entering in the usual follow-up of the patient
Study NCT02299713 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.
Study NCT02299713 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.